logo-loader
viewMaxCyte Inc

MaxCyte deal puts it at the forefront of developments in the cutting edge arena of gene editing

The company’s technology will be used to accelerate the “discovery, development, manufacturing and commercialisation of next-generation, cell-based medicines”.

dna.jpg
A great deal has been talked about CRISPR–Cas9 and the potential to edit faulty genes

AIM-listed MaxCyte Inc (LON:MXCT) could be at centre of some exciting developments in the cutting edge arena of gene editing.

For the company’s technology will be used to accelerate the “discovery, development, manufacturing and commercialisation of next-generation, cell-based medicines”.

According to a press release issued Tuesday CRISPR Therapeutics (NASDAQ:CRSP) and its joint-venture with Bayer AG, a company called Casebia Therapeutics, have picked up a licence to use MaxCyte’s technology.

Under the terms of the agreement, CRISPR Therapeutics and Casebia will get non-exclusive commercial-use rights to MaxCyte's cell engineering platform.

With it they plan to develop CRISPR-Cas9-based therapies for blood-related diseases and a rare genetic disorder called severe combined immunodeficiency.

MaxCyte will receive upfront, milestone and sales-based payments from any products its platform helps develop.

"The initiation of this commercial license agreement with CRISPR Therapeutics and Casebia, both leaders in gene editing, marks a very important milestone for MaxCyte in executing our business strategy and demonstrates the value of our platform and our intellectual property, as well as our ability to collaborate effectively with companies commercialising cell therapies," said Doug Doerfler, chief executive of MaxCyte.

A great deal has been talked about CRISPR–Cas9 and the potential to edit faulty genes.

But there are wider applications for the technology as this extract from the journal Nature explained.

“What CRISPR offers, and biologists desire, is specificity: the ability to target and study particular DNA sequences in the vast expanse of a genome,” it said.

“And editing DNA is just one trick that it can be used for. Scientists are hacking the tools so that they can send proteins to precise DNA targets to toggle genes on or off, and even engineer entire biological circuits — with the long-term goal of understanding cellular systems and disease.”

Quick facts: MaxCyte Inc

Price: 112 GBX

AIM:MXCT
Market: AIM
Market Cap: £64.28 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of MaxCyte Inc named herein, including the promotion by the Company of MaxCyte Inc in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

MaxCyte Inc gearing up for phase I study of potential cancer breakthrough

Doug Doerfler, chief executive of MaxCyte Inc (LON:MXCT), tells Proactive they're in a strong financial position as they prepare for the launch of a phase I clinical trial of a cancer treatment which helps to deploy the body’s own immune defences to combat strains of the killer...

on 23/1/18

2 min read